State Street Corp grew its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 14.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,486,585 shares of the company’s stock after purchasing an additional 583,094 shares during the period. State Street Corp owned 2.20% of TherapeuticsMD worth $23,647,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Schwab Charles Investment Management Inc. raised its holdings in shares of TherapeuticsMD by 10.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after purchasing an additional 67,855 shares during the period. Carl Domino Inc bought a new position in shares of TherapeuticsMD during the second quarter worth about $235,000. Stifel Financial Corp grew its position in shares of TherapeuticsMD by 377.9% during the second quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock worth $10,820,000 after acquiring an additional 1,622,668 shares during the last quarter. Bamco Inc. NY grew its position in shares of TherapeuticsMD by 126.8% during the second quarter. Bamco Inc. NY now owns 850,000 shares of the company’s stock worth $4,479,000 after acquiring an additional 475,200 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. grew its position in shares of TherapeuticsMD by 45.5% during the second quarter. Candriam Luxembourg S.C.A. now owns 480,000 shares of the company’s stock worth $2,530,000 after acquiring an additional 150,000 shares during the last quarter. 72.54% of the stock is currently owned by institutional investors.
In other TherapeuticsMD news, Director Tommy G. Thompson acquired 5,000 shares of TherapeuticsMD stock in a transaction dated Wednesday, August 30th. The stock was bought at an average price of $5.99 per share, for a total transaction of $29,950.00. Following the transaction, the director now owns 3,555 shares in the company, valued at approximately $21,294.45. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 23.92% of the company’s stock.
TXMD has been the subject of several recent research reports. Deutsche Bank AG initiated coverage on shares of TherapeuticsMD in a research report on Friday, July 21st. They set a “buy” rating and a $10.00 price target for the company. Cantor Fitzgerald restated a “buy” rating and set a $33.00 price target on shares of TherapeuticsMD in a research report on Monday, September 4th. BidaskClub upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Friday, September 8th. Morgan Stanley initiated coverage on shares of TherapeuticsMD in a research report on Friday, September 8th. They set an “equal weight” rating and a $6.00 price target for the company. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $10.00 price target on shares of TherapeuticsMD in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. TherapeuticsMD presently has an average rating of “Buy” and an average price target of $14.72.
TRADEMARK VIOLATION WARNING: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2017/11/15/state-street-corp-raises-holdings-in-therapeuticsmd-inc-txmd.html.
TherapeuticsMD, Inc. (NASDAQ:TXMD) opened at $5.87 on Wednesday. TherapeuticsMD, Inc. has a 12-month low of $3.50 and a 12-month high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The company had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million. During the same quarter last year, the firm posted ($0.13) EPS. The business’s revenue for the quarter was down 19.7% on a year-over-year basis. equities research analysts forecast that TherapeuticsMD, Inc. will post -0.37 earnings per share for the current fiscal year.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD, Inc. (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.